

12-Nov-2024

Eli Lilly and Company Limited

8 Arlington Square West
Downshire Way
Bracknell
RG12 1PU
England

Dr Olivia Smith
Berkshire Hospital
11 Hillberry
Bracknell
RG12 5EG

www.lilly.com/uk
Tel: 0203 1620044

Email: uk_team_gbmailgps@lilly.com

Dear Dr Olivia Smith,

Company Reference Number: GB202455660052

Re: Mounjaro (tirzepatide) – Gender patient: Female [Name: Claudia Martins/Initials: CM, DOB: 13-Oct-2024] who experienced Diarrhea

On 12-Oct-2024 the company received this adverse event report via our (tirzepatide) patient support programme. The patient gave us permission to follow up on this report and they provided your details as their treating doctor. I trust it is acceptable to contact you for follow-up for this case.

As part of our company's research, collection of post-marketing safety information on medicines is vital for the continuing improvement of our understanding of their use in normal clinical practice. As part of our commitment to patient safety, Lilly collects and collates information on adverse drug events. This data is transmitted to regulatory authorities such as the MHRA and is used to update prescribing information and to ensure that we are able to provide healthcare providers and patients with the most comprehensive advice available on our medicines.

Lilly advises that all patients are informed if an adverse event has been reported that relates to them.

We would be grateful if you could please provide the following information and return it in the enclosed pre-paid envelope, **or forward to the doctor concerned**, and return to us.

- Question 1
- Question 2
- Question 3

Eli Lilly & Company UK are appreciative of any information you are able to provide. As a marketing authorisation holder, we rely on reports from HCPs and consumers regarding patient experience to continuously monitor the safety profile of our products accurately, thereby ensuring that HCPs, public, and regulators are kept informed as to the risks associated with any given product and any actions that can mitigate them.

Thank you for your co-operation, we appreciate the time and trouble taken to assist us.

Yours sincerely,



Eli Lilly and Company Limited

8 Arlington Square West
Downshire Way
Bracknell
RG12 1PU
England

www.lilly.com/uk

Tel: 0203 1620044

Email: uk_team_gbmailgps@lilly.com

Global Patient Safety

Encs Pre-paid envelope

DATA PROTECTION NOTICE: All the information and personal data you share with Lilly will be protected and kept confidential in line with Company policies and local regulations. The information you provide will be used for the purpose of drug safety surveillance and may be shared with health authorities. Full privacy notice can be found here: <https://privacynotice.lilly.com>